Deblitane and Alcohol/Food Interactions
There are 5 alcohol/food/lifestyle interactions with Deblitane (norethindrone).
norethindrone Alcohol (Ethanol)
Minor Drug Interaction
Information for this minor interaction is available on the professional version.
norethindrone food
Moderate Food Interaction
Grapefruit juice may increase the blood levels of certain medications such as norethindrone. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with norethindrone. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
estrogens/progestogens - fluid retention
Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.
References
- Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102
- "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
- "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
- "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Climara (estradiol)." Berlex Laboratories (2001):
- "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories (2001):
- "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals (2001):
- "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals (2001):
- "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
- "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
- "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
- "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn (2001):
- "Product Information. Megace (megestrol)." Bristol-Myers Squibb (2001):
- "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
- "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn (2001):
- "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
- "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc (2001):
- "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC (2001):
- "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals (2006):
High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, Moderate plausibility
progestogens - hyperlipidemia
Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent. Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.
References
- Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985): 216-9
- Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32
- Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6
- Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987): 573-77
- Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986): 587-94
- Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993): 207-14
- "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
- "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
- "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
- "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
- "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
Obesity
Minor Potential Hazard, Moderate plausibility
progestogens - weight gain
Progestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients attempting to lose weight.
References
- Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102
- Amatayakul K, Sivasomboon B, Thanangkul O "A study of the mechanism of weight gain in medroxyprogesterone acetate users." Contraception 22 (1980): 605-22
- "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
- "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
- "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
- "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
- "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
Deblitane drug interactions
There are 246 drug interactions with Deblitane (norethindrone).
Deblitane disease interactions
There are 12 disease interactions with Deblitane (norethindrone) which include:
- abnormal genital bleeding
- hepatic neoplasms
- breast malignancy
- liver disease
- thromboembolism
- depression
- fluid retention
- glucose intolerance
- retinal thrombosis
- thyroid function tests
- hyperlipidemia
- weight gain
More about Deblitane (norethindrone)
- Deblitane consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (11)
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: contraceptives
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.